The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...

Galapagos NV is abandoning its small molecule roots to focus on cell therapy and at the same time splitting in two, with the spinout company, dedicated to acquiring a portfolio of assets, taking the ...

Belgian biotech company Galapagos NV plans to spin off part of its operations, creating a new listed firm with approximately ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

the Royalty Agreement, under which Galapagos will gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to Gilead on net sales of ...

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

CET; Galapagos NV. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In addition, Galapagos ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

The split-up of Galapagos is only the latest shake-up in the company in recent years. Other major events have included the ...